IL135922A0 - Anaesthetic formulation - Google Patents

Anaesthetic formulation

Info

Publication number
IL135922A0
IL135922A0 IL13592298A IL13592298A IL135922A0 IL 135922 A0 IL135922 A0 IL 135922A0 IL 13592298 A IL13592298 A IL 13592298A IL 13592298 A IL13592298 A IL 13592298A IL 135922 A0 IL135922 A0 IL 135922A0
Authority
IL
Israel
Prior art keywords
saccharide
amount
additional non
anesthetic agent
anaesthetic formulation
Prior art date
Application number
IL13592298A
Other languages
English (en)
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9724506.2A external-priority patent/GB9724506D0/en
Priority claimed from GBGB9818109.2A external-priority patent/GB9818109D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of IL135922A0 publication Critical patent/IL135922A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
IL13592298A 1997-11-19 1998-11-19 Anaesthetic formulation IL135922A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9724506.2A GB9724506D0 (en) 1997-11-19 1997-11-19 Levobupivacaine and its use
GBGB9818109.2A GB9818109D0 (en) 1998-08-19 1998-08-19 Anaesthetic Formulation
PCT/GB1998/003479 WO1999025349A1 (en) 1997-11-19 1998-11-19 Anaesthetic formulation

Publications (1)

Publication Number Publication Date
IL135922A0 true IL135922A0 (en) 2001-05-20

Family

ID=26312628

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13592298A IL135922A0 (en) 1997-11-19 1998-11-19 Anaesthetic formulation

Country Status (17)

Country Link
US (1) US5932597A (de)
EP (1) EP1032390B1 (de)
JP (1) JP2001522888A (de)
KR (1) KR100695588B1 (de)
CN (1) CN1131033C (de)
AT (1) ATE253913T1 (de)
AU (1) AU740914B2 (de)
BR (1) BR9814883A (de)
CA (1) CA2308495C (de)
DE (1) DE69819770T2 (de)
DK (1) DK1032390T3 (de)
ES (1) ES2209217T3 (de)
HU (1) HU228143B1 (de)
IL (1) IL135922A0 (de)
NO (1) NO328684B1 (de)
PT (1) PT1032390E (de)
WO (1) WO1999025349A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824161D0 (en) * 1998-11-04 1998-12-30 Darwin Discovery Ltd Drug formulation
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
SI2415484T1 (sl) 2004-09-17 2014-10-30 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
US20060270708A1 (en) * 2005-05-25 2006-11-30 Navinta Llc Novel process for preparation of isotonic aqueous injection of ropivacaine
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
JP2011506319A (ja) 2007-12-06 2011-03-03 デュレクト コーポレーション 疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
JP2016508956A (ja) * 2012-05-10 2016-03-24 セリックスビオ プライヴェート リミテッド 局所疼痛の治療のための組成物と治療法
AU2014233453A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
FI3331508T3 (fi) * 2015-07-13 2024-11-14 Neon Laboratories Ltd Levobupivakaiinihydrokloridin hyperbaarinen liuosinjektio, joka käsittää levobupivakaiinihydrokloridia
US12274794B2 (en) 2016-07-06 2025-04-15 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
JP2023515918A (ja) 2020-01-13 2023-04-17 デュレクト コーポレーション 不純物が低減された徐放性薬物送達システム及び関連の方法
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods
WO2025175174A1 (en) * 2024-02-14 2025-08-21 The Children's Medical Center Corporation 2'-6'-pipecoloxylidide as a sensory-selective anesthetic

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8802564D0 (sv) * 1988-07-08 1988-07-08 Astra Ab New synergistic preparations and a new method of alleviation of pain
AU694453B2 (en) * 1993-10-13 1998-07-23 Darwin Discovery Limited Analgesic agent and its use
GB9321061D0 (en) * 1993-10-13 1993-12-01 Chiroscience Ltd Analgestic agent and its use

Also Published As

Publication number Publication date
DK1032390T3 (da) 2004-03-15
DE69819770T2 (de) 2004-09-23
DE69819770D1 (de) 2003-12-18
EP1032390B1 (de) 2003-11-12
HUP0004665A3 (en) 2004-05-28
JP2001522888A (ja) 2001-11-20
EP1032390A1 (de) 2000-09-06
NO20002545L (no) 2000-05-18
KR100695588B1 (ko) 2007-03-14
ES2209217T3 (es) 2004-06-16
WO1999025349A1 (en) 1999-05-27
HU228143B1 (en) 2012-12-28
CA2308495A1 (en) 1999-05-27
BR9814883A (pt) 2000-10-03
KR20010032241A (ko) 2001-04-16
ATE253913T1 (de) 2003-11-15
CN1279607A (zh) 2001-01-10
NO20002545D0 (no) 2000-05-18
PT1032390E (pt) 2004-04-30
HK1026848A1 (en) 2000-12-29
CA2308495C (en) 2009-01-06
CN1131033C (zh) 2003-12-17
NO328684B1 (no) 2010-04-26
US5932597A (en) 1999-08-03
HUP0004665A2 (hu) 2001-04-28
AU740914B2 (en) 2001-11-15
AU1168499A (en) 1999-06-07

Similar Documents

Publication Publication Date Title
IL135922A0 (en) Anaesthetic formulation
MXPA03006841A (es) 4-fluoro-n-indan-2-il-benzamida y su uso como producto farmaceutico.
EP0202621A2 (de) Lokale Behandlung von Schuppen, Dermatitis seborrhoeica und Psoriasis
DE59204010D1 (de) Durch silberkolloid stabilisiertes wasserstoffperoxidenthaltendes mundhygienemittel.
EP0690722A4 (de) Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren
PL319603A1 (en) Stable aqueous alpha interferon preparations
DE68906153D1 (de) Humanes relaxinpraeparat.
EP1295607A4 (de) Antitumoreffekt-verstärker
JP2001522888A5 (de)
AU2003298179A1 (en) Lens care composition and method
PL357132A1 (en) Stable, nasally, orally or sublingually applicable pharmaceutical preparation
ATE273033T1 (de) Stabilisierte ophthalmische wasserstoffperoxidlösung
EA200001010A1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
BR0209206A (pt) Clatrato de hidrato de azitromicina com 1,2-propileno glicol, processo para a sua preparação e composição farmacêutica compreendendo o mesmo
ES2171444T3 (es) Una solucion intravenosa que disminuye las perdidas de proteinas y de agua corporales.
HU9403736D0 (en) Topical application composition
ATE348621T1 (de) Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte
DE60213464D1 (de) Amlopidinbezylat-tabletten mit verbesserter stabilität
GB2306885B (en) Supersaturated Pharmaceutical Compositions
ES2159967T3 (es) Medicamento que contiene acido delta-aminolevulinico.
SE9003181D0 (sv) Use of heparin fraction
ATE311891T1 (de) Cytidin-diphosphocholin gegen diabetische neuropathie
KR960701643A (ko) 겸상 적혈구 빈혈증, 말라리아 및 외인적으로 유발된 백혈구 감소증 치료를 위한 콜로이드성 이산화규소의 용도(Use of Collodidal Silicon Dioxide for Treating Sickle-Cell Anemia, Malaria and Exogenously Induced Leukopenias)
MX9603766A (es) Metodos de administracion de benzamidas n-substituidas o fenotiazinas.
BG94567A (en) Medicaments for the treatment of aids and method for its application

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
EXP Patent expired